P. Schnabel (Heidelberg, Germany), A.-P. Meert (Brussels, Belgium)
Clinical significance of hypoxia inducible factor-1α and VEGF expression in lung cancer
E. Karetsi, T. Kerenidi, M. Ioannou, G. Koukoulis, K. Gourgoulianis, P. A. Molyvdas, E. Paraskeva (Larissa, Greece)
|   |
Association of polymorphisms in the genes of the urokinase plasminogen activation system with susceptibility to and severity of nonsmall cell lung cancer
Y. L. Lee, W. Chen, S. C. Chen, W. E. Cheng, C. M. Shih (Taichung, Taiwan)
| |
Expression of caveolin-1 and ttf-1 in lung adenocarcinomas with various histological subtypes
K. Laitakari, R. Sormunen, R. Mäkitaro, P. Pääkkö, R. Bloigu, R. Kaarteenaho (Oulu, Finland)
| |
Lung cancer and metabolism: a role for glucagon?
J. Vrioni, T. Theodoropoulos (Athens, Greece; Tampa, United States Of America)
| |
Epigenetic inactivation of checkpoint kinase 2 gene in nonsmall cell lung cancer and its relationship with clinicopathological features
S. Y. Lee, S. S. Yoo, J. H. Lee, C. Y. Jung, S. I. Cha, C. H. Kim, T. H. Jung, D. S. Kim, J. Y. Park (Daegu, Gumi, Republic Of Korea)
| |
C/EBP-β expression in mesothelioma cells is regulated by mitogen activated protein kinase p38-β and –gamma
J. Zhong, D. Lardinois, M. Tamm, M. Roth (Basel, Switzerland)
| |
Methylation for cystic fibrosis transmembrane regulator gene in nonsmall cell lung cancer
G. E. Lee, S. J. Kwon, J. W. Son, E. Choi, M. J. Na, Y. J. Kim, H. M. Cho (Daejeon, Republic Of Korea)
| |
Globo h tumor antigen expression is associated with blood group a1 and negative prognosis in NSCLC
L. H. Schmidt, A. Kuemmel, S. Biesterfeld, A. Faldum, D. Weiss, S. Koschmieder, C. Mueller-Tidow, C. Mueller-Tidow, R. Wiewrodt (Muenster, Mainz, Erlangen, Germany)
| |
Exhaled aldehydes as markers of disease in lung cancer patients
E. Straker, C. Loesecken, P. Fuchs, W. Miekisch, J. Schubert (Rostock, Germany)
| |
Autophagic cell death of the nutrient deprivation augmented by cytotoxic drugs in lung cancer cell
E. T. Jeong, K. E. Hwang, H. J. Jo, J. H. Jeong, J. H. Park, H. J. Kim, H. R. Kim, S. H. Yang (Iksan, Republic Of Korea)
| |
Endoplasmic reticulum Ca2+-homeostasis is altered in lung cancer cell lines and contributes to cisplatin-resistance
A. Bergner, K. Schroedl, J. Kellner, R. M. Huber (Munich, Germany)
| |
The expression and biological significance of PD-L1 on lung cancer cell lines
J. A. Huang, C. Chen, C. Y. Mu (suzhou, China)
| |
A novel ex vivo model for the evaluation of hypoxic adaptation in non-small cell lung cancer using surgery explants
K. Leithner, C. Wohlkoenig, E. Stacher, J. Lindenmann, H. Popper, A. Hrzenjak, A. Olschewski, H. Olschewski (Graz, Austria)
| |
Expression of claudins 1, 2, 3, 4, 5 and 7 in lung cancer
H. Merikallio, R. Kaarteenaho, T. Harju, R. Mäkitaro, P. Paakko, Y. Soini (Oulu, Kuopio, Finland)
| |
Importance of clusterin expression at tissue level for the prognosis of non-small cells lung cancer
F. Panico, C. Casali, G. Rossi, S. Astancolle, E. S. Storelli, A. Corti, U. Morandi, F. Luppi, L. M. Fabbri (Modena, Italy)
| |
Proteomic analysis of human small cell lung cancer tissues
H. C. Jeong, E. K. Kim, J. H. Lee, G. I. L. Kim, K. S. Cho, K. H. Chung (Sungnam, Republic Of Korea)
| |
p53 mutations do not predict response to paclitaxel in metastatic non-small cell lung carcinoma
M. Petrovic, Z. Lazic, I. Cekerevac, L. Novkovic, V. Cupurdija (Kragujevac, Republic Of Serbia)
| |
Changes and significance of CD4+CD25+ T cells in patients with lung cancer
Y. Zhou, D. Xue, X. Tan, Y. Wu, Z. Wang (Guangzhou, China)
| |
Does expression of excision repair cross-complementation group 1 correlate between primary nonsmall cells lung cancer tumor and metastases?
J. B. Roseau, A. M. Taseï, J. B. Souraud, D. Figarella-Branger, P. Astoul (Toulon, Marseille, France)
| |